BioInvent International AB (publ)
SSE:BINV.ST
16.58 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | BioInvent International AB (publ) |
Symbool | BINV.ST |
Munteenheid | SEK |
Prijs | 16.58 |
Beurswaarde | 1,091,036,952 |
Dividendpercentage | 0% |
52-weken bereik | 14 - 32 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Martin Welschof Ph.D. |
Website | https://www.bioinvent.com |
An error occurred while fetching data.
Over BioInvent International AB (publ)
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)